{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:33:39Z","timestamp":1791290019212,"version":"4.3.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1053\/j.ajkd.2010.05.023","type":"journal-article","created":{"date-parts":[[2010,8,15]],"date-time":"2010-08-15T04:54:04Z","timestamp":1281848044000},"page":"823-831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["Warfarin Dosing in Patients With Impaired Kidney Function"],"prefix":"10.1053","volume":"56","author":[{"given":"Nita A.","family":"Limdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit A.","family":"Limdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa F.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Allon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Mark","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1053\/j.ajkd.2010.05.023_bib1","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.ajkd.2010.05.023_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/aje\/kwp151","article-title":"Defining incident chronic kidney disease in the research setting: the ARIC Study","volume":"170","author":"Bash","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/clpt.2009.137","article-title":"Public health consequences of chronic kidney disease","volume":"86","author":"Weiner","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.ajkd.2010.05.023_bib4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2006.05.021","article-title":"Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease","volume":"48","author":"Weiner","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2010.05.023_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2007111207","article-title":"Dilemmas in the management of atrial fibrillation in chronic kidney disease","volume":"20","author":"Reinecke","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2010.05.023_bib6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1681\/ASN.2009070715","article-title":"ESRD as a window into America's cost crisis in health care","volume":"20","author":"Knauf","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2010.05.023_bib7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1681\/ASN.2008080860","article-title":"Prediction, progression, and outcomes of chronic kidney disease in older adults","volume":"20","author":"Anderson","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2010.05.023_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/clpt.2008.208","article-title":"Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications","volume":"85","author":"Zhang","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1053\/j.ajkd.2010.05.023_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/MNH.0b013e3283136732","article-title":"Altered nonrenal drug clearance in ESRD","volume":"17","author":"Nolin","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2010.05.023_bib10","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1681\/ASN.2006010035","article-title":"Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure","volume":"17","author":"Michaud","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2010.05.023_bib11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","article-title":"The effect of chronic renal failure on drug metabolism and transport","volume":"4","author":"Dreisbach","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6 suppl","key":"10.1053\/j.ajkd.2010.05.023_bib12","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"11","key":"10.1053\/j.ajkd.2010.05.023_bib13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-147-11-200712040-00006","article-title":"Medication use leading to emergency department visits for adverse drug events in older adults","volume":"147","author":"Budnitz","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0009-9236(03)00015-8","article-title":"Cytochrome P4502C9 activity in end-stage renal disease","volume":"73","author":"Dreisbach","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1053\/j.ajkd.2010.05.023_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/j.ajkd.2007.06.017","article-title":"Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates","volume":"50","author":"Elliott","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2010.05.023_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.ajkd.2007.10.034","article-title":"Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients","volume":"51","author":"Genovesi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2010.05.023_bib17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2010.05.023_bib18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2217\/14622416.9.10.1445","article-title":"VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans","volume":"9","author":"Limdi","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1053\/j.ajkd.2010.05.023_bib19","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2217\/14622416.8.11.1535","article-title":"Factors influencing warfarin dose requirements in African-Americans","volume":"8","author":"Momary","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1053\/j.ajkd.2010.05.023_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2010.05.023_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.pharmtox.45.120403.095821","article-title":"Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics","volume":"45","author":"Rettie","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"10.1053\/j.ajkd.2010.05.023_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2010.05.023_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/clpt.2009.190","article-title":"When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective","volume":"86","author":"Huang","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2010.05.023_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/17410541.4.2.157","article-title":"Influence of CYP2C9 genotype on warfarin dose among African American and European Americans","volume":"4","author":"Limdi","year":"2007","journal-title":"Pers Med"},{"issue":"2","key":"10.1053\/j.ajkd.2010.05.023_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.clpt.6100290","article-title":"Influence of CYP2C9 and VKORC1 1173C\/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin","volume":"83","author":"Limdi","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1053\/j.ajkd.2010.05.023_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1525-139X.2003.03011.x","article-title":"The effect of chronic renal failure on hepatic drug metabolism and drug disposition","volume":"16","author":"Dreisbach","year":"2003","journal-title":"Semin Dial"},{"issue":"2","key":"10.1053\/j.ajkd.2010.05.023_bib28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1681\/ASN.V122326","article-title":"Downregulation of hepatic cytochrome P450 in chronic renal failure","volume":"12","author":"Leblond","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2010.05.023_bib29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/bja\/71.2.282","article-title":"Effect of renal failure on drug metabolism by the liver","volume":"71","author":"Elston","year":"1993","journal-title":"Br J Anaest"},{"issue":"10","key":"10.1053\/j.ajkd.2010.05.023_bib30","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1681\/ASN.2009010082","article-title":"ESRD impairs nonrenal clearance of fexofenadine but not midazolam","volume":"20","author":"Nolin","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J"},{"issue":"9663","key":"10.1053\/j.ajkd.2010.05.023_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(09)60205-1","article-title":"Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial","volume":"373","author":"Young","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2010.05.023_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"7645","key":"10.1053\/j.ajkd.2010.05.023_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","article-title":"Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials","volume":"336","author":"Strippoli","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1053\/j.ajkd.2010.05.023_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1053\/j.ajkd.2010.05.023_bib36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx00025a009","article-title":"Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions","volume":"5","author":"Rettie","year":"1992","journal-title":"Chem Res Toxicol"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/clpt.2009.187","article-title":"Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function","volume":"86","author":"Spruill","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/clpt.2009.124","article-title":"Use of the MDRD Study equation to estimate kidney function for drug dosing","volume":"86","author":"Stevens","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1053\/j.ajkd.2010.05.023_bib39","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1681\/ASN.2009020171","article-title":"Measured GFR as a confirmatory test for estimated GFR","volume":"20","author":"Stevens","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2010.05.023_bib40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ki.2009.158","article-title":"When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase","volume":"76","author":"Jain","year":"2009","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2010.05.023_bib41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.ajkd.2008.11.019","article-title":"Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention","volume":"53","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2010.05.023_bib42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/ki.2009.143","article-title":"Impact of reporting estimated glomerular filtration rate: it's not just about us","volume":"76","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2010.05.023_bib43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/j.ajkd.2008.07.032","article-title":"Reporting estimated GFR: a laboratory perspective","volume":"52","author":"Miller","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib44","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1053\/j.ajkd.2007.12.035","article-title":"A review of albumin binding in CKD","volume":"51","author":"Meijers","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"10.1053\/j.ajkd.2010.05.023_bib45","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/eurheartj\/ehp195","article-title":"Kidney function estimated from serum creatinine and cystatin C and peripheral arterial disease in NHANES 1999-2002","volume":"30","author":"Selvin","year":"2009","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1053\/j.ajkd.2010.05.023_bib46","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1373\/clinchem.2009.128397","article-title":"Cystatin C and cardiovascular risk","volume":"55","author":"Taglieri","year":"2009","journal-title":"Clin Chem"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib47","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2215\/CJN.05281008","article-title":"Cystatin C levels in U.S. adults, 1988-1994 versus 1999-2002: NHANES","volume":"4","author":"Foley","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2010.05.023_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.ajkd.2007.11.018","article-title":"Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD","volume":"51","author":"Stevens","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2010.05.023_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ndt\/gfm661","article-title":"A comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two","volume":"23","author":"Tidman","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1053\/j.ajkd.2010.05.023_bib50","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2010.05.023_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2458-8-117","article-title":"Prevalence of chronic kidney disease in population-based studies: systematic review","volume":"8","author":"Zhang","year":"2008","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1053\/j.ajkd.2010.05.023_bib52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2010.05.023_bib53","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2005111204","article-title":"Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study","volume":"18","author":"Wattanakit","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2010.05.023_bib54","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"Weiner","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2010.05.023_bib55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ahj.2009.06.031","article-title":"Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study","volume":"158","author":"Watanabe","year":"2009","journal-title":"Am Heart J"},{"issue":"4","key":"10.1053\/j.ajkd.2010.05.023_bib56","first-page":"523","article-title":"Prevalence of ICD-9-CM codes for chronic kidney disease in individuals with cardiovascular disease risk factors","volume":"22","author":"Mahajan","year":"2009","journal-title":"J Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2010.05.023_bib57","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCULATIONAHA.108.191259","article-title":"Heart disease and stroke statistics\u20142009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638610010474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638610010474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:55:15Z","timestamp":1759456515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638610010474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0272638610010474"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2010.05.023","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Warfarin Dosing in Patients With Impaired Kidney Function","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2010.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}